Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs

Br J Cancer. 1998 Apr;77(7):1089-96. doi: 10.1038/bjc.1998.181.

Abstract

We examined the steady-state levels of mRNA for gamma-glutamylcysteine synthetase (gamma-GCS), multidrug resistance-associated protein (MRP) and human canalicular multispecific organic anion transporter (cMOAT) in human lung cancer specimens to elucidate their roles in relation to platinum drug resistance in vivo. Seventy-six autopsy samples (38 primary tumours and their corresponding normal lung tissues) obtained from 38 patients were analysed using the quantitative reverse transcription polymerase chain reaction (RT-PCR) method. Both subunits (heavy and light subunits) of gamma-GCS expression levels of normal lung and tumour tissues exposed to platinum drugs during life were significantly higher than those of non-exposed tissues, whereas only the MRP expression levels of tumours were elevated in association with ante-mortem platinum drug exposure. The gamma-GCS and MRP expression levels correlated significantly. The cMOAT expression levels did not correlate with ante-mortem platinum drug exposure. Next, we monitored gamma-GCS heavy subunit expression levels in peripheral mononuclear cells of eight previously untreated lung cancer patients after platinum drug administration, which revealed that these drugs induced gamma-GCS expression in vivo. These results suggest that gamma-GCS expression is induced by platinum drugs in vivo and/or the physiological stress response to xenobiotics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP-Binding Cassette Transporters / drug effects*
  • ATP-Binding Cassette Transporters / metabolism
  • Adult
  • Aged
  • Aged, 80 and over
  • Anion Transport Proteins
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Carrier Proteins / drug effects*
  • Carrier Proteins / metabolism
  • Cisplatin / pharmacology*
  • Cisplatin / therapeutic use
  • DNA Topoisomerases, Type I / drug effects
  • DNA Topoisomerases, Type I / metabolism
  • Female
  • Glutamate-Cysteine Ligase / drug effects*
  • Glutamate-Cysteine Ligase / metabolism
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / genetics*
  • Male
  • Middle Aged
  • Multidrug Resistance-Associated Proteins
  • Neoplasm Proteins / drug effects*
  • Neoplasm Proteins / metabolism
  • RNA, Messenger / drug effects*
  • RNA, Messenger / metabolism

Substances

  • ATP-Binding Cassette Transporters
  • Anion Transport Proteins
  • Antineoplastic Agents
  • Carrier Proteins
  • Multidrug Resistance-Associated Proteins
  • Neoplasm Proteins
  • RNA, Messenger
  • DNA Topoisomerases, Type I
  • Glutamate-Cysteine Ligase
  • Cisplatin